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OBJECTIVES The purpose of this study was to determine the pathogenic factors and molecular mechanisms
involved in fibrosis of the atria.
BACKGROUND Fibrosis is an important component of the pathophysiology of atrial fibrillation, especially
when the arrhythmia is associated with heart failure (HF) or atrial dilation.
METHODS We used a rat model of myocardial infarction (MI) complicated by various degrees of left
ventricular dysfunction and atrial dilation to study fibrosis and matrix metalloproteinase
(MMP) activity in the left atrial (LA) myocardium by means of histologic, Western blot,
zymographic, and immunohistologic techniques.
RESULTS Three months after surgical ligature of the left coronary artery, 27 rats had a large MI, 12 were
in mild HF, and 15 in severe HF. Both groups had LA enlargement at the echocardiography.
Masson’s trichrome and picrosirius staining of tissue sections revealed marked fibrosis at the
periphery of trabeculae and also surrounding myolytic myocytes, in both mild and severe HF.
In mild HF, the activity and expression of the matrilysin MMP-7 were increased (122%),
whereas in severe HF, both MMP-7 (211%) and the gelatinase MMP-2 (187%) were
up-regulated. There were no changes in the expression or activity of MMP inhibitors,
TIMP-1, -2, and -4. Immunostaining of cryosections showed that MMP-2 was present in
the interstitial spaces, whereas MMP-7 accumulated in myolytic myocytes.
CONCLUSIONS Hemodynamic overload of the atria is an important pathogenic factor of fibrosis; MMP-7
appears to be involved in the early stage of this tissue remodeling process. (J Am Coll
Cardiol 2003;42:336–44) © 2003 by the American College of Cardiology Foundation
Atrial fibrillation (AF) is the most frequent form of arrhyth-
mia in clinical practice (1). Its pathophysiology is complex
and usually combines triggering by focal extrasystoles, acti-
vation of the nervous system, and a substratum that allows
micro-reentry of the electrical impulse. The substratum is
characterized by functional and structural alterations of the
myocardium, including action potential shortening and
hypertrophied and dedifferentiated myocytes showing ex-
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tensive myolysis (2–4). When AF complicates heart failure
(HF), fibrosis becomes a predominant component of atrial
remodeling. For instance, in the canine model of pacing-
induced HF, marked fibrosis of the atrial myocardium
contributes to local impairment of electrical conduction and,
in turn, to AF persistence (5). Tissue alterations with
fibrosis are also present in the right atria (RA) of patients in
sinus rhythm during HF or with a dilated atrium, suggest-
ing that hemodynamic factors participate in atrial myocar-
dium remodeling (4,6,7).
Matrix metalloproteinases (MMPs) play a crucial role in
extracellular matrix homeostasis in a number of physiologic
and pathologic situations, including during HF (8–12).
These proteolytic enzymes are regulated at transcriptional
levels and by endogenous physiologic inhibitors such as
tissue inhibitors of metalloproteinases (TIMPs) (8,10,12).
During HF, there is increased activity of various MMPs
such as: 1) collagenases that degrade fibrillar collagens; 2)
gelatinases that degrade type IV and fibrillar collagens as
well as non-collagenous constituents of the basement mem-
brane (9,10,12). Moreover pharmacologic inhibition of
MMPs prevents left ventricle (LV) dilation and pump
dysfunction (11,13,14).
In the present study, we used the rat model of myocardial
infarction (MI) characterized by various degrees of systolic
and diastolic LV dysfunction (15–17) to address the follow-
ing questions: 1) is chronic alteration of the working
conditions of the atria an important pathogenic factor for
fibrosis, and 2) how are MMPs and their inhibitors
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(TIMPs) regulated during the atrial myocardial remodeling
associated with LV pump dysfunction?
METHODS
Experimental MI. Animal care complied with the Princi-
ples of Laboratory Animal Care formulated by the National
Society for Medical Research, and the study was authorized
(#006235) by the French Agriculture Ministry. Myocardial
infarction was induced in 10-week-old male Wistar rats
(Charles River, France) by left coronary artery ligation, as
previously described (15). Briefly, animals were anesthetized
with 50 mg/kg of 2% Rompun solution (Bayer-Pharma,
Puteau, France) and 10 mg/kg Imalgene 500 (Me´rial, Lyon,
France), then intubated and ventilated. After left thoracot-
omy, the ligation of the descending anterior left coronary
artery was performed. This procedure infarcted about 30%
to 40% of the LV. A sham operation was performed in eight
rats (Sh) by everting the heart from the thorax without
performing coronary artery ligature. Three months after
surgery, the rats were euthanized, and their left atria (LA)
were frozen in liquid nitrogen for biochemical and immu-
nohistochemistry studies or fixed for 24 h in buffered
formalin before being embedded in paraffin for histologic
examination.
Echocardiographic study. Transthoracic echocardiogra-
phy was performed in rats anesthetized with 2% isoflurane
aerosol in air enriched with 50% O2 using an echocardio-
graph (Toshiba Powervision 6000, SSA 370 A) equipped
with an 8- to 14-MHz linear transducer. The LV and the
LA were imaged in parasternal long-axis view at a frequency
of 120 Hz and measured in M-mode. End-diastolic diam-
eter (LVDd) was defined as the largest LV diameter,
systolic diameter (LVDs) was defined as the smallest LV
diameter, and the fractional shortening was calculated as
[(LVDdLVDs)/LVDd]  100. Left atrial diameter was
defined as the distance between the posterior wall of the
aorta and the posterior wall of the LA (16).
Histologic study. Sections (7 m thick) of fixed LA (10%
formol) were stained with picrosirius red F3BA or Masson’s
trichrome.
Holter monitoring. A hermetically sealed transmitter
(DataScience International, St. Paul, Minnesota) was im-
planted intraperitoneally with electrodes placed in a “lead
2-like” position. The one-channel electrocardiographic sig-
nal (1 kHz) was digitized, amplified and emitted with a
radiofrequency carrier. Rats were housed in a cage placed on
a receiver that captured the signal independently of animal
activity. Acquisition and analysis were performed using the
software Chart v4.1.2 (PowerLab, AdInstruments, Colo-
rado Springs, Colorado).
Immunohistochemistry. Cryosections (7 m) of LA were
used for double indirect immunofluorescence labeling as
previously described (4). The following primary antibodies
were used: mouse anti-rabbit sarcomeric alpha-actinin an-
tibody (1/400, Sigma Chemical Co, St. Louis, Missouri);
polyclonal chicken anti-human MMP-2 (5 g/ml; Chemi-
con, Euromedex, Souffelweyersheim, France) or polyclonal
rabbit anti-human MMP-7 (10 g/ml; Chemicon). As
secondary antibodies we used Texas-red-conjugated sheep
anti-mouse IgG (1/20 Amersham Biosciences), FITC con-
jugated donkey anti-rabbit IgG (1/20; Amersham Bio-
sciences, Orsay, France) and FITC conjugated donkey
anti-chicken IgG (1/50; Jackson ImmunoResearch, Balti-
more, Maryland). Slides were examined with a fluorescence
microscope.
ANP and cGMP assays. Plasma concentrations of atrial
natriuretic peptide (ANP) were measured after solid-phase
extraction on Bond Elut cartridges by radioimmuno-
assay with anti-atrial natriuretic factor antibodies (personal
products), standard atrial natriuretic factor (1-28, Sigma
Aldrich, Lyon, France), and iodinated atrial natriuretic
peptide (ANP) (NEN Life Science, Courtaboeuf, France).
Urinary and extruded cGMP levels were measured with a
radioimmunoassay kit (3H cyclic guanosine monophosphate
assay, Amersham, London, UK) (18). The day before
euthanasia, rats were placed in metabolic cages for collection
of 15-h urine samples in order to normalize cGMP con-
centration with urine output (nmol/ml).
MMP zymography and TIMP reverse zymography. Pro-
teins were extracted from frozen atrial tissues, crushed and
homogenized on ice in 0.05 mol/l Tris-HCl, pH 7.5,
containing 0.01 mol/l CaCl2, 2 mol/l guanidium chloride,
and 0.2% Triton X-100, dialyzed against 0.05 mol/l Tris-
HCl, pH 7.5, and 0.2% Triton X-100 for 48 h at 4°C. The
amount of protein was determined using the Bradford assay.
Ten micrograms of proteins were subjected to SDS-PAGE
in gels containing 0.1% gelatin or alpha-casein (Sigma
Aldrich) for MMP-2 and MMP-7 analysis, respectively.
For TIMP-1 and TIMP-2 measurements, 160 ng/ml
proMMP-2 (Euromedex, France) were added in gelatin
gels; for TIMP-4, 320 ng/ml proMMP-7 were added in
casein gels. A solution of TIMPs was used as reference.
Quantification was performed by densitometry analysis with
the NIH Image 1.61 program. A sample used as a standard
was loaded in each gel in order to normalize density values,
and data were expressed as arbitrary units (AUs). The
specificity of the protease activity was checked by incubating
gelatin and casein gels with EDTA (30 mmol/l) or Pefabloc
Abbreviations and Acronyms
AF  atrial fibrillation
ANP  atrial natriuretic peptide
AU  arbitrary unit
HF  heart failure
LA  left atria/atrial
LV  left ventricle
MI  myocardial infarction
MMP  matrix metalloproteinase
RA  right atria/atrial
TIMP  tissue inhibitor of metalloproteinase
337JACC Vol. 42, No. 2, 2003 Boixel et al.
July 16, 2003:336–44 Fibrosis and Atrial Remodeling During HF
(VWR, Fontenay, France) to block MMP and serine
protease activities, respectively (19,20).
Western blot. The same procedure was used to extract
proteins for Western blot and zymography studies. Electro-
phoresis was performed as described by Laemmli on 10%
polyacrylamide gel in non-reducing conditions (30 g per
lane). Proteins were transferred to polyscreen PVDF mem-
branes (NEN, Life Science Products). Non-specific binding
sites were blocked with 4% BSA. Antibodies against
MMP-2, -7, -13, and TIMP-1, -2, and -4 (Chemicon)
were used at 1 g/ml. Proteins were detected with an
enhanced chemiluminescence method (NEN, Life Science)
using horseradish peroxidase. A sample used as a standard
was loaded in each gel in order to normalize density values;
data were expressed as AUs. To control the quantity of
proteins transferred to the membrane, Coomassie-blue-
stained blot was analyzed by densitometric scanning with
National Institutes of Health software.
Data analysis. Data are expressed as means  SEM. For
intergroup comparisons we used a one-way analysis of
variance followed by Scheffe´’s test, with statistical signifi-
cance accepted at p  0.05.
RESULTS
Clinical, morphologic, and biologic characteristics of
infarcted rats. Three months after surgery, 12 rats showed
signs of severe HF (S) including body weight loss, increased
heart and right ventricle weights and, often, pleural effusion
(Table 1). In this group, plasma concentrations of ANP
were increased in keeping with urinary accumulation of
cGMP (15,18). The remaining 15 infarcted rats showed no
physical signs of congestive HF. Their heart weight/body
weight ratio was enhanced compared with the sham-
operated rats, but less than in the S; their plasma ANP and
urinary cGMP concentrations were not significantly in-
creased. They were considered to be in mild HF (M).
M-mode echocardiograms obtained with two-dimensional
guidance from a long-axis heart view revealed atrial dilation
in both M and S groups compared to Sh, more pronounced
in S rats (Table 2, Fig. 1). The LA weight/body weight ratio
was increased in both M and S rats. Of note, the RA
weight/body weight ratio was also increased in infarcted rats
(Table 1). In S rats, the LV was markedly dilated and its
fractional shortening was reduced (Table 2). No episode of
AF was detected during 24 h electrocardiogram recording
performed in 11 shams and 11 infarcted rats (5 M and 6 S).
Marked structural alteration of atrial myocardium of
infarcted rats. Figures 2A and 2B show tissue sections of
LA stained with Masson’s trichrome procedure. In control
specimens (n  4), narrow myocytes were well aligned and
surrounded by little interstitial tissue (Fig. 2A). In contrast,
sections of atria from both M (n  4) and S (n  4) rats
were almost entirely occupied by large myocytes organized
in tortuous strips (Fig. 2B). In both M and S, there was a
large increase in connective tissue that accumulated between
bundles of fibers. The collagen also accumulated within the
trabeculae in the intercellular spaces, forming large septa.
This was clearly revealed by picrosirius staining, which
showed that myocytes were entirely surrounded by collage-
nous septa (Figs. 2C and 2D). Histologic examination of
RA of infarcted rats also revealed fibrosis around trabeculae
and myocytes (n  3, data not shown). Extensive structural
alterations of myocytes were also observed in diseased atria,
as illustrated by confocal microphotography of tissue sec-
tions labeled with antibodies directed against sarcomeric
alpha-actinin, a protein of the Z-line (Figs. 2E and 2F). In
Table 1. Morphologic and Biologic Parameters
Sham
Mild Heart Failure
(M)
Severe Heart Failure
(S)
n 8 15 12
BW, g 624  2 611  4 574  4*‡
HW/BW, mg/g 2.7  0.02 3.2  0.03 4.3  0.04*‡
LVW/BW, mg/g 2.1  0.1 2.0  0.1 2.1  0.05
RVW/BW, mg/g 0.4  0.02 0.6  0.08* 0.9  0.07†‡
LAW/BW, mg/g 0.08  0.01 0.1  0.02* 0.2  0.04*‡
RAW/BW, mg/g 0.1  0.08 0.14  0.01* 0.15  0.02*
(HW-LVW)/BW, mg/g 0.58  0.02 1.10  0.04* 1.43  0.03*
ANP, pmol·ml1 52.8  1.1 76.9  2.9 175.6  9.0†‡
Urinary cGMP, nmol/ml 5.7  0.7 6.1  0.3 19.1  3.6*‡
All values are means  SEM. n  the number of animals in each group; significant difference vs. sham, *p  0.05, †p  0.001;
significant difference vs. M, ‡p  0.05.
ANP  atrial natriuretic peptide; BW  body weight; cGMP  cyclic guanosine monophosphate; HW  heart weight;
LAW  left atrial weight; LVW  left ventricular weight; RVW  right ventricular weight.
Table 2. Echocardiographic Parameters
Sham
Mild Heart
Failure (M)
Severe Heart
Failure (S)
n 4 10 6
LAD, mm 5.7  0.3 7.1  0.2* 9.7  0.1*†
LVDd, mm 7.5  0.3 9.4  0.5* 12.9  0.7*†
LVDs, mm 5.1  0.1 6.8  0.1 10.7  0.4*†
Fractional shortening, % 32  1 27  3* 17  6*†
All values are means  SEM; n  the number of animals in each group. Significant
difference vs. sham, *p  0.05; significant difference vs. M, †p  0.05.
LAD  left atrial diameter; LVDd  end-diastolic left ventricle diameter;
LVDs  end-systolic left ventricle diameter.
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control atria, the staining was organized in a regularly
striated network that filled the entire cell body, whereas
myocytes in diseased atria showed extensive myofibrillar
disruption (Fig. 2F).
Up-regulation of MMPS in diseased atria. Figure 3A
shows that when zymogram studies were performed with
gelatin as the proteolytic substrate, a proteolytic activity was
detected at around 72 kD, corresponding to gelatinase A
(MMP-2) (the guanidium of the extraction buffer induced
activation of MMP-2, explaining that both proform and
active forms of the MMP were visible; the three bands were
used for quantification) (Fig. 3A). MMP-2 activity was
detected in all samples and was significantly increased only
in atria from S rats (8.9  0.9 AU vs. 3.1  0.7 AU in S (n
 4) and Sh (n  4), respectively; p  0.05).
The main proteolytic activity detected on casein zymo-
gram was at around 28 kD, corresponding to the matrilysin
MMP-7 (Fig. 3A). MMP-7 activity was barely detectable
in sham-operated animals (0.9  0.09 AU [n  4]), while
a strong band was obtained with the atria of M rats (2.0 
0.4 AU, [n 4]; p 0.05) and an even stronger band in the
S group (2.8  0.3 AU [n  4]; p  0.001). No other
proteolytic activity was observed with gelatin and casein
zymograms.
Changes in MMP activities ran parallel to changes in
MMP-2 and MMP-7 protein expression, as shown with
Western blots performed with antibodies directed against
72 kD MMP-2 and 28 kD MMP-7 (Fig. 3B). Densito-
metric analysis of the blots showed a significant increase in
MMP-2 expression in the S group only (62.3 10.3 AU vs.
166.9  3.8 AU, in Sh [n  4] and S [n  4] rats; p 
0.05). Faint MMP-7 protein was detected in Sh (19.9 1.3
AU, n  4), while its expression was markedly enhanced in
both M (60.5  12.5 AU [n  4]; p  0.05) and S (66.6
 12.9 AU [n  4]; p  0.05) animals. There was also a
trend towards an increase in the expression of interstitial
collagenase MMP-13 in atria of infarcted rats (3.8  0.6
AU in Sh (n  5); 12.2  4.3 AU in M (n  4); 6.8  2.8
AU [n  5] in S; p  NS) (Fig. 3B).
Lack of changes of TIMP activity in atria from infarcted
rats. The regulation of TIMPs was first examined by
studying the MMP inhibitory activity of protein samples by
reverse zymography. In gels containing gelatin and
proMMP-2, two bands were detected at around 28 and 26
Figure 1. Two-dimensional echocardiographic image (parasternal long-axis view) of the heart in sham-operated (A) and infarcted (severe heart failure) (C)
rats. M-mode echocardiograms were obtained from the two-dimensional long-axis views, with a cross-section at the level of the aortic valve in
sham-operated (B) and infarcted (D) rats. Ao  aorta; LA  left atria; LV  left ventricle.
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kD, corresponding to TIMP-1 and TIMP-2, respectively
(Fig. 3C). When zymogram analysis was performed with
casein as substrate supplemented with proMMP-7 (21),
only a weak inhibition of proteolytic activity corresponding
to TIMP-4 (24 kD) was detected (data not shown). There
was no significant difference in the intensity of three bands
between groups of rats. Western blots performed with
anti-TIMP-1 and -TIMP-2 antibodies, detected bands at
their expected molecular weight: 100 and 98 kD, respec-
tively (Fig. 3D). After reduction of protein samples with
beta-mercaptoethanol in order to suppress TIMP-MMP
complexes, there was no significant difference in band
intensity between groups.
MMP-7 accumulated in atrial myocytes of infarcted
rats. As shown in Figures 4A and 4B in both normal and
diseased myocardial samples, positive MMP-2 staining was
observed at the periphery of trabeculae. In diseased atria, the
staining was also seen around bundles of fibers (Fig. 4B).
Figure 2. Masson’s trichrome (A, B) and picrosirius staining (C, D) of atrial sections from control (A, C) and infarcted rats in severe heart failure (B) and
mild heart failure (D). Fibrosis is especially visible around myocytes of diseased atria. Sarcomeric alpha-actinin immunostaining of atrial cryosections from
control (E) and infarcted (F) rats in severe heart failure (confocal microscopy) showing myolysis of myocytes of diseased atria. Bar  50 m (A, B) and
10 m (C to F).
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We then examined the tissue localization of the matrilysin
MMP-7 in sections of the same specimen. Sections of
control atria showing a typical regular cross-striated orga-
nization of sarcomeric alpha-actinin (Fig. 4C) were entirely
negative with anti-MMP-7 antibody (Fig. 4E). In contrast,
sections of diseased atria stained positively with anti-
MMP-7 antibody. The staining was observed in most of the
myolytic myocytes, and was distributed irregularly through-
out the cell body and at the cell periphery (Fig. 4F). Note
that the interstitial space was negative with MMP-7
staining.
DISCUSSION
After experimental MI in the rat, and despite the lack of
arrhythmia, the progression of LV dysfunction had a
marked impact on the LA, with fibrosis and numerous
enlarged myocytes with myolysis as the main features. The
metalloproteinases MMP-2 and MMP-7 appear to be
involved in this extracellular matrix remodeling.
Hemodynamic overload of the atria is an important
pathogenic factor of fibrosis. Our finding of an important
fibrosis during the atrial remodeling associated with LV
dysfunction is reminiscent of the accumulation of interstitial
tissue observed in the fibrillating atria of dogs with pacing-
induced HF or mitral valve stenosis (5,22). In contrast, it
conflicts with the lack of extracellular matrix remodeling
observed in experimental AF induced by atrial pacing (3).
Marked fibrosis around dystrophic myocytes is also observed
in RA of patients with chronic AF that often complicates
HF or valve diseases, and also in those in sinus rhythm with
a hemodynamic overload and dilated atria (4,6,7,23). Alto-
gether, these studies point to a specific role of atrial loading
conditions in fibrosis. The RA of infarcted rats also exhibits
a fibrotic remodeling that was probably the indirect conse-
quence of LV dysfunction via pulmonary circulation adap-
tation and hemodynamic overload of the right side of the
heart (24). Hypertrophied myocytes with extensive myolysis
Figure 3. MMP and TIMP activities in atrial myocardium. (A) Gelatin (MMP-2) and casein (MMP-7) zymogram showing the proteolytic activity in
sham-operated (Sh), and infarcted rats in mild (M) or severe (S) heart failure. (B) Western blot of proteins from Sh, M, and S rats probed with
anti-MMP-2, anti-MMP-7, and anti-MMP-13 antibodies. Analysis of TIMP-1 and -2 activity by reverse zymography (C) and (D) Western blot
performed with anti-TIMP-1, anti-TIMP-2 in Sh, M, and S rats.
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can be also the consequence of the hemodynamic overload
of the atria (3,6), together with oxidative injury (25). In
addition to local changes in the loading conditions of the
atria, various neuromediators or hormones probably play an
important role in this extracellular matrix remodeling. For
instance, the renin-angiotensin system is up-regulated dur-
ing HF, and there is an increased density of angiotensin
type-2 receptors in fibrillating human atrial myocardium
(26). Moreover, it has been shown that angiotensin-
converting enzyme inhibition attenuates atrial remodeling
and fibrosis in the experimental dog model of HF (27,28).
Different patterns of MMP expression during atrial
remodeling. Matrix metalloproteinases appear to be key
actors in interstitial tissue alterations of diseased atrial myocar-
dium. However, the up-regulation of the gelatinase MMP-2
was observed only in animals with severe congestive HF,
possibly because at this stage, factors known to stimulate
MMP-2, such as mechanical stress, endothelin-1, the renin-
angiotensin system, or cytokines accumulate (8,10,12,29).
We also observed marked up-regulation of the matrilysin
MMP-7 in both groups of infarcted rats. This MMP, which
is produced by various tissues (30), has the widest range of
substrates, including all fibrillar collagens (31) and compo-
nents of the basement membrane (32), which are required
for cell-cell cohesion and alignment. Overloaded rat atrial
myocardium showed marked fibrosis between myocytes and
the loss of myocyte cohesion that may be associated with
alterations of the basement membrane, as observed during
the atrial remodeling during feline cardiomyopathy (33). In
dilated atria, enlarged myocytes with myolysis appear to be
an important source of MMP-7. The expression of this
protease may be either one component of the process of cell
hypertrophy and dedifferentiation (3,6), as reported in
denervated muscle cells (34), or the consequence of changes
in cytoskeletal architecture of myocytes (20). The interstitial
space of atrial myocardium where fibroblasts are present was
negative for the MMP-7 immunostaining. However, we
have recently observed that isolated rat atrial fibroblasts
Figure 4. Frozen atrial sections stained with anti-alpha-actinin sarcomeric (red), anti-MMP-2 (green) (A, B), and anti-MMP-7 (green) (E, F) from sham
(A, C, E) and infarcted (B, D, F) rats in severe heart failure. Arrow in panel F indicates peripheral cell staining. Note that distinct magnifications were
used in panel A, B (20) and C to F (40); Bar  20 m.
342 Boixel et al. JACC Vol. 42, No. 2, 2003
Fibrosis and Atrial Remodeling During HF July 16, 2003:336–44
maintained 24 h in culture secrete large amounts of both
MMP-2 and MMP-7, indicating that in some circum-
stances, these cells can also be a source of MMPs (unpub-
lished data). Both the marked fibrosis surrounding trabec-
ulae and bundles of myofibers and the trend towards an
increase in the MMP-13 expression indicate that interstitial
collagenases are also likely to be key actors in this remod-
eling process.
The observation that MMPs are up-regulated in the atria
three months after MI suggests that a large part of the
extracellular matrix remodeling of the LA is due to the
progression of LV dysfunction. In the LV after MI, in
addition to early activation of MMP-1, -2, -3 and -9, there
is also a delayed activation of MMPs, including the MT-
MMP, that is probably involved in the remodeling of the
myocardium (11).
The MMP up-regulation observed here was not matched
by changes in TIMPs that bind specifically to the catalytic
domain of MMPs and form an important control system for
overall MMP activity (10,12). Thus, the lack of TIMP
up-regulation and, in turn, the altered MMP/TIMP stoi-
chiometry, could result in a loss of control of MMP activity
and thereby contribute to the increase in MMP activity in
diseased atria (35). A similar lack of adaptive TIMP
responses to increased MMP activity has been reported in
ventricular myocardium during progression of HF (10,12)
and was attributed to the accumulation of cytokines that can
alter the TIMP/MMP equilibrium (36).
Potential clinical significance. Changes in extracellular
matrix may have a profound impact on atrial electrical and
mechanical properties (37–39). Fibrosis in the intercellular
spaces that form collagenous septa could alter the conduc-
tion of electrical influxes such as the transverse conduction
velocity (5,38) and contribute to the loss of myocyte-
myocyte coordination. None of the infarcted rats of the
present study had an AF. This may be because the size of
the rat atria, even during HF, is not sufficient for the
constitution of circuits of reentry of the electrical impulse in
keeping with the wavelength theory, or because some
triggering factors are lacking. The lack of episodes of AF in
this model indicates that the structural remodeling that is
believed to constitute part of the substratum of AF can be
present in the absence of the arrhythmia. This may provide
an explanation for the vulnerability to AF observed in
clinical settings associated with atrial hemodynamic over-
load. Thus, study of effects of pharmacologic MMP inhi-
bition on the progression of atrial remodeling and the
occurrence of AF is warranted.
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